New Migraine Drug Telcagepant Delayed
Merck & Company's new Migraine drug Telcagepant which was recently hoping to win FDA approval, has been delayed. The small phase IIa clinical study was stopped after participants' liver enzymes were high while taking the medication on a daily basis. Telcagepant is an antagonist of the receptor for... Read more












